Quantum BioPharma is trading at $3.33 (-9.78%) now, amid what appears to be broader risk-off trading.
- August 17, 2026, second-quarter results showed operating expenses down 53% year over year and approximately $9.5 million in liquidity.
- The Nasdaq Composite is down 1.44% and the S&P 500 is down 0.63%.
- FDA clearance for the Lucid-MS Phase 2 trial remains a recent positive catalyst; no new negative company-specific announcement was found.